HC Wainwright set a $7.00 price target on Nabriva Therapeutics (NASDAQ:NBRV) in a research note released on Sunday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
“We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s).”,” HC Wainwright’s analyst commented.
Several other research firms have also recently issued reports on NBRV. Gabelli raised Nabriva Therapeutics from a sell rating to a hold rating and set a $2.00 price target for the company in a research note on Thursday, May 2nd. Zacks Investment Research raised Nabriva Therapeutics from a hold rating to a buy rating and set a $2.50 price target for the company in a research note on Wednesday, August 14th. ValuEngine raised Nabriva Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Northland Securities reissued a buy rating and issued a $12.50 price target on shares of Nabriva Therapeutics in a research note on Thursday, August 8th. Finally, Needham & Company LLC reissued a buy rating and issued a $10.00 price target (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $7.06.
Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.04. Nabriva Therapeutics had a negative return on equity of 139.52% and a negative net margin of 3,602.24%. The company had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.88 million. On average, equities research analysts predict that Nabriva Therapeutics will post -1.1 EPS for the current year.
Several institutional investors have recently made changes to their positions in NBRV. Two Sigma Advisers LP acquired a new stake in shares of Nabriva Therapeutics in the fourth quarter valued at $37,000. Jane Street Group LLC purchased a new stake in shares of Nabriva Therapeutics during the fourth quarter valued at $29,000. FMR LLC lifted its holdings in shares of Nabriva Therapeutics by 514.2% during the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after purchasing an additional 1,542,700 shares during the last quarter. Fosun International Ltd purchased a new stake in shares of Nabriva Therapeutics during the first quarter valued at $1,593,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Nabriva Therapeutics by 30.0% during the second quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 3.10% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.